Files in this Data Supplement:
Fig. S1. Flow chart of a single experimental round and the microfluidic device layout. Fig. S2. A hypothetical splenic retention threshold was drawn at 0.65 based on the typical RBC life span of balb/c mice as well as statistical analysis. Fig. S3. (A) Statistical interpretation on Fig. 3C. (B to E) Splenic minced RBC deformability profiles were fitted by using both unimodal and bimodal distributions. Fig. S4. Parameters were estimated by the maximum likelihood method, and the fitted results were listed. Fig. S5. Hemoglobin concentrations of 12 healthy mice receiving CQ treatment and 12 healthy mice receiving PBS placebo were monitored on day 1 and day 5. Fig. S6. (A) Microfluidic velocity-based deformability measurement is compared with a filtration column that mimics iRBC retention in human spleen. (B) Mouse RBCs are 25% smaller than human RBCs. Fig. S7. The diameter (A), surface area, volume, and sphericity (B) of normal RBCs after CQ treatment in vivo are quantified based on microscopic imaging (A) and micropipette aspiration (B). Fig. S8. Microscopic images of RBC morphology after in vivo CQ treatment. Fig. S9. Surface area, volume, and sphericity measurements on different stages of iRBCs before (A) and after (B) CQ treatment. Fig. S10. Membrane shear modulus of different stages of iRBCs from venous blood, from splenic blood, or from CQ-treated venous blood.
PDF, 920K